Cover Image
市場調查報告書

組蛋白去乙醯酶1 (EC 3.5.1.98) :開發中產品分析

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 363131
出版日期 內容資訊 英文 138 Pages
訂單完成後即時交付
價格
Back to Top
組蛋白去乙醯酶1 (EC 3.5.1.98) :開發中產品分析 Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H1 2018
出版日期: 2018年03月20日 內容資訊: 英文 138 Pages
簡介

本報告提供組蛋白去乙醯酶1 (EC 3.5.1.98)的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • 4SC AG
  • Acetylon Pharmaceuticals, Inc.
  • Chipscreen Biosciences Ltd
  • Curis, Inc.
  • GlaxoSmithKline Plc
  • HitGen LTD
  • IRBM Science Park SpA
  • Italfarmaco S.p.A.
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Mirati Therapeutics Inc.
  • Oncolys BioPharma Inc.
  • Sigma-Tau S.p.A.
  • Syndax Pharmaceuticals, Inc.
  • TetraLogic Pharmaceuticals

藥物簡介

暫停的計劃

最新消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1374TDB

Summary:

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase family and is a component of the histone deacetylase complex. It also interacts with retinoblastoma tumor-suppressor protein and this complex is a key element in the control of cell proliferation and differentiation. Together with metastasis-associated protein-2 MTA2, it deacetylates p53 and modulates its effect on cell growth and apoptosis. It plays an important role in transcriptional regulation, cell cycle progression and developmental events.

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) pipeline Target constitutes close to 29 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 4, 6, 12 and 2 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Dermatology, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Follicular Lymphoma, Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lung Cancer, Melanoma, Myelodysplastic Syndrome, Neuroblastoma, Relapsed Acute Myeloid Leukemia, Thalassemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Bile Duct Cancer (Cholangiocarcinoma), Colon Cancer, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Liver Cancer, Mantle Cell Lymphoma, Metastatic Renal Cell Carcinoma, Mycosis Fungoides, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Sickle Cell Disease, Solid Tumor, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Adenoid Cystic Carcinoma (ACC), Alopecia, Alzheimer's Disease, Anaplastic Thyroid Cancer, Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Bladder Cancer, Bone Disorders, Burkitt Lymphoma, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), CNS Lymphoma, Colorectal Cancer, Depression, Duchenne Muscular Dystrophy, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leiomyosarcoma, Liver Fibrosis, Lung Adenocarcinoma, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, Neuroendocrine Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Psychiatric Disorders, Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sezary Syndrome, Skin Cancer, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Systemic Lupus Erythematosus and Thyroid Cancer.

The latest report Histone Deacetylase 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Overview
    • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
    • 4SC AG
    • AlfaSigma SpA
    • Celgene Corp
    • Chipscreen Biosciences Ltd
    • Curis Inc
    • HitGen LTD
    • IRBM Science Park SpA
    • Italfarmaco SpA
    • Medivir AB
    • MEI Pharma Inc
    • Merck & Co Inc
    • Mirati Therapeutics Inc
    • Syndax Pharmaceuticals Inc
    • Zhejiang Hisun Pharmaceutical Co Ltd
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drug Profiles
    • 4SC-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-1035 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-1071 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-738 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-957 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crocetin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-3158 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • entinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fimepinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • givinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HG-3001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • largazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mocetinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pracinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RCY-1305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RCY-1497 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RCY-1992 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remetinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • resminostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit KDM1A, HDAC1 and HDAC2 for Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC1 and 2 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-3595 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tucidinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vorinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Dormant Products
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Discontinued Products
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 07, 2018: University of Colorado: Treatment for Diastolic Dysfunction
      • Jan 31, 2018: Positive DSMB safety review of 4SC's pivotal RESMAIN study of resminostat in CTCL
      • Jan 11, 2018: Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)
      • Jan 10, 2018: Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer
      • Dec 20, 2017: 4SC receives Pediatric Investigation Plan Waiver for resminostat in CTCL from the European Medicines Agency
      • Dec 13, 2017: 4SC receives milestone payment from Immunic
      • Dec 11, 2017: Italfarmaco Presents Positive Phase II Study Results for Givinostat in Polycythemia Vera Patients at the ASH Annual Meeting
      • Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting
      • Dec 01, 2017: Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition
      • Nov 11, 2017: Syndax Announces Presentation of ENCORE 601 Data at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting
      • Nov 07, 2017: Syndax to Present Data On Entinostat at SITC 32nd Annual Scientific Meeting
      • Oct 13, 2017: Remetinostat Phase II Data Demonstrate Efficacy on Skin Lesions, Reduction of Itching and High Tolerability in Patients With Early-stage MF-type CTCL
      • Oct 12, 2017: Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients
      • Oct 10, 2017: Resminostat demonstrates potential to significantly alleviate itching in CTCL patients
      • Oct 05, 2017: Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..4), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by 4SC AG, H1 2018
  • Pipeline by AlfaSigma SpA, H1 2018
  • Pipeline by Celgene Corp, H1 2018
  • Pipeline by Chipscreen Biosciences Ltd, H1 2018
  • Pipeline by Curis Inc, H1 2018
  • Pipeline by HitGen LTD, H1 2018
  • Pipeline by IRBM Science Park SpA, H1 2018
  • Pipeline by Italfarmaco SpA, H1 2018
  • Pipeline by Medivir AB, H1 2018
  • Pipeline by MEI Pharma Inc, H1 2018
  • Pipeline by Merck & Co Inc, H1 2018
  • Pipeline by Mirati Therapeutics Inc, H1 2018
  • Pipeline by Syndax Pharmaceuticals Inc, H1 2018
  • Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Dormant Products, H1 2018 (Contd..2), H1 2018
  • Dormant Products, H1 2018 (Contd..3), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top